Literature DB >> 20179908

Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Marcello Solinas1, Gianluigi Tanda, Carrie E Wertheim, Steven R Goldberg.   

Abstract

RATIONAL: Although delta-9-tetreahydrocannabinol (THC)-induced elevations in accumbal dopamine levels are believed to play an important role in the abuse-related effects of cannabis, little direct evidence has been provided that the dopaminergic system is involved in the psychotropic effects of THC.
OBJECTIVE: The objective of this study is to investigate whether drugs activating or blocking the dopaminergic system modulate the discriminative effects of THC. METHODS AND
RESULTS: In rats that had learned to discriminate 3 mg/kg of THC from vehicle injections, the indirect dopaminergic agonists cocaine and amphetamine, the D(1)-receptor agonist SKF-38393, and the D(2)-receptor agonists quinpirole and apomorphine did not produce significant THC-like discriminative effects. However, both cocaine and amphetamine and D(2)-, but not the D(1)-, receptor agonists, augmented THC discrimination. Neither the D(1)-receptor antagonist SCH-23390 nor the D(2)-receptor antagonist raclopride reduced the discriminative effects of THC, even at doses that significantly depressed baseline operant responding. However, the D(2)-, but not the D(1)-, antagonist counteracted the augmentation of THC's discriminative effects produced by cocaine and amphetamine. We hypothesized that release of anandamide by activation of D(2) receptors was responsible for the observed augmentation of THC discrimination. This hypothesis was supported by two findings. First, the cannabinoid CB(1)-receptor antagonist rimonabant blocked quinpirole-induced augmentation of THC discrimination. Second, inhibition of anandamide degradation by blockade of fatty acid amide hydrolase augmented the THC-like effects of quinpirole.
CONCLUSIONS: Dopamine does not play a major role in THC discrimination. However, activation of the dopaminergic system positively modulates the discriminative effects of THC, possibly through D(2)-induced elevations in brain levels of anandamide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179908      PMCID: PMC2834964          DOI: 10.1007/s00213-010-1789-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior.

Authors:  H Steiner; C R Gerfen
Journal:  Exp Brain Res       Date:  1998-11       Impact factor: 1.972

2.  Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra.

Authors:  E D French; K Dillon; X Wu
Journal:  Neuroreport       Date:  1997-02-10       Impact factor: 1.837

3.  delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors.

Authors:  E D French
Journal:  Neurosci Lett       Date:  1997-05-02       Impact factor: 3.046

4.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  The role of dopamine receptor subtypes in the discriminative stimulus effects of amphetamine and cocaine in rats.

Authors:  M Filip; E Przegaliński
Journal:  Pol J Pharmacol       Date:  1997 Jan-Feb

Review 6.  Cannabinoid transmission and reward-related events.

Authors:  E L Gardner; S R Vorel
Journal:  Neurobiol Dis       Date:  1998-12       Impact factor: 5.996

7.  Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study.

Authors:  J P Chen; W Paredes; J H Lowinson; E L Gardner
Journal:  Neurosci Lett       Date:  1991-08-05       Impact factor: 3.046

Review 8.  Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic dopamine system.

Authors:  David W Self
Journal:  Neuropharmacology       Date:  2004       Impact factor: 5.250

9.  Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids.

Authors:  M Diana; M Melis; G L Gessa
Journal:  Eur J Neurosci       Date:  1998-09       Impact factor: 3.386

10.  A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission.

Authors:  Diego Centonze; Natalia Battista; Silvia Rossi; Nicola B Mercuri; Alessandro Finazzi-Agrò; Giorgio Bernardi; Paolo Calabresi; Mauro Maccarrone
Journal:  Neuropsychopharmacology       Date:  2004-08       Impact factor: 7.853

View more
  11 in total

1.  Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.

Authors:  Marco Orrú; César Quiroz; Xavier Guitart; Sergi Ferré
Journal:  Neuropharmacology       Date:  2011-07-05       Impact factor: 5.250

Review 2.  Dopamine and addiction: what have we learned from 40 years of research.

Authors:  Marcello Solinas; Pauline Belujon; Pierre Olivier Fernagut; Mohamed Jaber; Nathalie Thiriet
Journal:  J Neural Transm (Vienna)       Date:  2018-12-19       Impact factor: 3.575

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

4.  Longitudinal predictors of cannabis use and dependence in offspring from families at ultra high risk for alcohol dependence and in control families.

Authors:  Shirley Y Hill; Bobby L Jones; Stuart R Steinhauer; Nicholas Zezza; Scott Stiffler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-01-12       Impact factor: 3.568

5.  Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.

Authors:  David R Schulze; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2012-02-29       Impact factor: 4.530

6.  Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride.

Authors:  R E Vann; D M Walentiny; J J Burston; K M Tobey; T F Gamage; J L Wiley
Journal:  Neuropharmacology       Date:  2011-10-31       Impact factor: 5.250

7.  Analysis of 14 endocannabinoids and endocannabinoid congeners in human plasma using column switching high-performance atmospheric pressure chemical ionization liquid chromatography-mass spectrometry.

Authors:  Cristina Sempio; Jelena Klawitter; Matthew Jackson; Francesca Freni; Ryan Shillingburg; Kent Hutchison; L Cinnamon Bidwell; Uwe Christians; Jost Klawitter
Journal:  Anal Bioanal Chem       Date:  2021-04-05       Impact factor: 4.142

8.  Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice.

Authors:  Maddalena Mereu; Valeria Tronci; Lauren E Chun; Alexandra M Thomas; Jennifer L Green; Jonathan L Katz; Gianluigi Tanda
Journal:  Addict Biol       Date:  2013-08-04       Impact factor: 4.280

Review 9.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

10.  Delineation of domains within the cannabinoid CB1 and dopamine D2 receptors that mediate the formation of the heterodimer complex.

Authors:  Shazina S Khan; Frank J S Lee
Journal:  J Mol Neurosci       Date:  2013-11-22       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.